Skip to main content
76°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Hims & Hers Health, Inc. Class A Common Stock
(NY:
HIMS
)
48.42
+0.44 (+0.92%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 7, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Hims & Hers Health, Inc. Class A Common Stock
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
34
35
Next >
How Compounded Treatments Are Helping Hims & Hers Customers Meet Their Weight Loss Goals
October 29, 2024
From
Hims & Hers
Via
Business Wire
Top 3 Stocks Institutions Are Buying Right Now
October 28, 2024
Despite the stock market trading at new all-time highs, institutions still find enough reason to buy more enormous stakes in three stocks.
Via
MarketBeat
Hims & Hers Stock Dropped: Here's What You Need to Know
October 24, 2024
The GLP-1 drama continues at Hims & Hers.
Via
The Motley Fool
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
October 23, 2024
Via
Benzinga
A Look Into Hims & Hers Health Inc's Price Over Earnings
October 22, 2024
Via
Benzinga
How Is The Market Feeling About Hims & Hers Health?
October 22, 2024
Via
Benzinga
This Is What Whales Are Betting On Hims & Hers Health
October 21, 2024
Via
Benzinga
Decoding 6 Analyst Evaluations For Hims & Hers Health
October 21, 2024
Via
Benzinga
Hims & Hers names Dr. Jessica Shepherd as Chief Medical Officer of Hers
October 21, 2024
From
Hims & Hers
Via
Business Wire
In-Depth Examination Of 6 Analyst Recommendations For Hims & Hers Health
October 21, 2024
Via
Benzinga
Why Hims & Hers' Incredible Growth Will Continue
October 18, 2024
GLP-1s get all the attention, but Hims & Hers' core business is where the rocket growth is.
Via
The Motley Fool
Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.
October 16, 2024
Hims & Hers has enjoyed a rally on an FDA decision regarding Eli Lilly's tirzepatide.
Via
Investor's Business Daily
Hims & Hers to Announce Third Quarter 2024 Financial Results on November 4, 2024
October 14, 2024
From
Hims & Hers
Via
Business Wire
What Is Going On With Hims & Hers Stock?
October 11, 2024
Big GLP-1 news could have an impact.
Via
The Motley Fool
Hims & Hers Health Stock Is Popping Monday: What's Behind The Move?
October 14, 2024
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would reconsider a decision barring drug compounders from selling their own...
Via
Benzinga
Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug
October 14, 2024
An industry group sued the FDA, claiming tirzepatide remains in shortage.
Via
Investor's Business Daily
Topics
Lawsuit
Where Does Hims & Hers Stock Go From Here?
October 12, 2024
Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright?
Via
The Motley Fool
2 Incredibly Cheap Growth Stocks to Buy Right Now
October 12, 2024
Look beyond the stock price at the business when shares are volatile.
Via
The Motley Fool
2 No-Brainer Growth Stocks to Buy With $500 Right Now
October 12, 2024
Consistently investing even moderate sums can grow your portfolio with time.
Via
The Motley Fool
Top 3 Stocks with Explosive Call Option Activity: What to Watch
October 10, 2024
Three stocks reported a surge in call option buying recently, showing investors that there could be a path to more upside potential, analysts agree
Via
MarketBeat
FDA Sparks Controversy With Sudden Removal Of Eli Lilly's Weight Loss Drug From Shortage List
October 08, 2024
FDA faces legal action after removing Tirzepatide from the shortage list without following required procedures, sparking concerns over patient access to the compounded diabetes and obesity treatment.
Via
Benzinga
Hims & Hers Stock Joins S&P 600: Is More Upside on the Horizon?
October 08, 2024
There is now a new reason to look into Hims & Hers stock for additional upside, including the new addition to the S&P 600 index alongside double-digit growth.
Via
MarketBeat
Topics
Stocks
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
October 08, 2024
Growth for its GLP-1 weight loss drugs continues to be robust.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
October 07, 2024
Via
Benzinga
Pfizer, Vista Outdoor, Duckhorn Portfolio And Other Big Stocks Moving Higher On Monday
October 07, 2024
Via
Benzinga
Hims & Hers Health Stock Is Rising Monday: What's Going On?
October 07, 2024
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday. The company is set to join to the S&P SmallCap 600 this week.
Via
Benzinga
Topics
Stocks
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
October 04, 2024
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's Q3 2024 revenue is expected to exceed projections as concerns rise over...
Via
Benzinga
Massive News for Hims & Hers Stock: The Truth About Today's Move
October 04, 2024
Hims & Hers may not be hurt by GLP-1 news the way investors think.
Via
The Motley Fool
2 Winning Growth Stocks That Are Screaming Buys Right Now
October 04, 2024
These top stocks are on a winning streak and have the businesses to keep it going.
Via
The Motley Fool
AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday
October 03, 2024
Via
Benzinga
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
34
35
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.